INDP Stock Analysis: Buy, Sell, or Hold?
INDP - Indaptus Therapeutics, Inc. Common Stock
$1.29
-0.09 (-6.52%)
▼
5d:
+20.56%
30d:
-53.43%
90d:
+21.7%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When INDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INDP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INDP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INDP is currently trading at $1.29, which is considered slightly low relative to its 30-day fair value range of $1.06 to $2.40.
Technical Outlook: Technically, INDP is in a downtrend. Immediate support is located at $0.92, while resistance sits at $1.58. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: INDP scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.00 (+675.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INDP is in a downtrend. Immediate support is located at $0.92, while resistance sits at $1.58. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: INDP scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.00 (+675.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.06 -
$2.40
Company Quality Score
54/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 675.2% below Wall St target ($10.00)
- CAUTION: Bottoming setup, but lagging the sector by 50% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.06 -
$2.40
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.92
Resistance Level
$1.58
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.29
Wall Street Target
$10.00
(+675.2%)
Share & Embed Analysis
Last updated: August 23, 2026 11:49 PM ET
Data refreshes hourly during market hours. Next update: 12:49 AM
Data refreshes hourly during market hours. Next update: 12:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INDP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 38 SELL |
